<DOC>
	<DOC>NCT01620762</DOC>
	<brief_summary>The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.</brief_summary>
	<brief_title>Phase III Cat-PAD Study</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Inclusion Criteria Male or female, aged 1265 years. Moderate to severe rhinoconjunctivitis on exposure to cats for at least 2 years. Subjects may optionally also have GINA Step 1 controlled asthma. Positive skin prick test to cat hair. Cat dander specific IgE â‰¥0.35 kU/L. Exclusion Criteria Asthma falling under the GINA definitions "partly controlled" and "uncontrolled" or Steps 2 to 5. FEV1 &lt;80% of predicted. Clinically significant confounding symptoms of allergy to seasonal allergens during the final evaluation period. Skin prick test 5 mm greater than the negative control to perennial allergens or animal dander (other than cat) which cannot be avoided during the study. Significant symptoms of another clinically relevant illness that is likely to affect scoring of rhinoconjunctivitis symptoms. Clinically relevant abnormalities detected on physical examination. History of severe drug allergy, severe angioedema or anaphylactic reaction to food.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cat allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
</DOC>